Apellis Pharmaceuticals, Inc. announced a corporate restructuring to drive growth of SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan), positioning Apellis for long-term success. This restructuring will include cost reduction initiatives that align with the Company?s near-term priorities and are expected to result in up to $300 million in total cost savings through 2024. Key elements of the plan include: Maximizing SYFOVRE?s global leadership in GA.
The Company remains focused on supporting the continued strong U.S. commercial launch of SYFOVRE and is preparing for potential ex-U.S. launches, with an anticipated decision on regulatory approval by the European Medicines Agency (EMA) in early 2024. In the first half of 2023, S…
Read the full article at: https://www.marketscreener.com/quote/stock/APELLIS-PHARMACEUTICALS-38607086/news/Apellis-Pharmaceuticals-Inc-Announces-Corporate-Restructuring-to-Drive-Growth-of-SYFOVRE-and-EMPAV-44721171/